RAD51 Inhibitor B02

SKU: orb1302680

Description

B02 is a small molecule inhibitor of the human RAD51 recombinase, exhibiting an IC50 of 27.4 µM. It is widely used in research to study DNA repair mechanisms, particularly homologous recombination, and has been applied in both in vitro assays and in vivo models to investigate cancer biology and potential therapeutic strategies.

Research Area

Cell Biology, Molecular Biology

Key Properties

• CAS Number: 1290541-46-6
• MW: 339.39
• Purity: 99.90% (May vary between batches)
• Formula: C₂₂H₁₇N₃O
• SMILES: O=c1n(Cc2ccccc2)c(\C=C\c2cccnc2)nc2ccccc12
• Target: Apoptosis,DNA/RNA Synthesis
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (5.89 mM);DMSO:33.9 mg/mL (99.89 mM)

Bioactivity

• Target IC50:
  RAD51:27.4 μM
• In Vivo:
  B02 substantially improves the therapeutic efficacy of cisplatin against tumor cells in vivo, demonstrating tolerability in mice at dosages up to 50 mg/kg without significant body weight reduction. Mice treated solely with B02 exhibited no tumor growth inhibition; however, those administered 4 mg/kg of cisplatin experienced a 33% reduction in tumor growth. Crucially, a combination treatment involving 50 mg/kg B02 and 4 mg/kg cisplatin resulted in a 66% decrease in tumor size.
• In Vitro:
  RAD51 Inhibitor B02 selectively inhibits human RAD51 (IC50 = 27.4 μM) without affecting its E. coli homologue RecA (IC50 > 250 μM). Combining B02 with cisplatin exhibits a potent cytotoxic effect on human breast cancer cells [MDA-MB-231].'

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

RAD51 Inhibitor B02, RAD-51 Inhibitor B02, RAD51, RNA Synthesis, RNASynthesis, Inhibitor, inhibit, Apoptosis, B 02, B02, B-02, DNA Synthesis, DNASynthesis

Compound Identifiers

PubChem CID

5738263